Results 11 to 20 of about 92,765 (246)

HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure

Viruses, 2022
Despite the availability of effective vaccines and antiviral therapy over the past two to three decades, chronic hepatitis B virus (HBV) infection remains a major global health threat as a leading cause of cirrhosis and liver cancer.
M. Moini, S. Fung
semanticscholar   +1 more source

Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection

Gut, 2021
Objective Hepatitis B virus (HBV)-specific T cells are main effector cells in the control of HBV infection and hepatitis B surface antigen (HBsAg) is suggested to be a critical factor in the impaired immune response, a hallmark of chronic HBV infection ...
E. Aliabadi, Melanie Urbanek-Quaing, B. Maasoumy, B. Bremer, Martina Grasshoff, Yang Li, Christian Niehaus, H. Wedemeyer, A. Kraft, M. Cornberg   +9 more
semanticscholar   +1 more source

Hepatitis B infection among hemodialysis patients in Al-Jazirah State: a seroepidemiological survey

Current Issues in Pharmacy and Medical Sciences, 2023
Hemodialysis patients are more susceptible to HBV infection because they have low immunity and can be inflicted through an improperly sterilized machine or through a tainted blood transfusion.
Moglad Ehssan H. O., Mohammed Hajir E. E., Ali Hatim T.O.   +2 more
doaj   +1 more source

How does the immunogenicity of hepatitis B vaccine change over the years in childhood?

Human Vaccines & Immunotherapeutics, 2021
Hepatitis B is the leading cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma worldwide. The incidence of HBV infection has significantly decreased with hepatitis B vaccination. Hepatitis B vaccine is administered to children at 0, 1 and
Gulsum Iclal Bayhan, Sidika Elif Balli, Hatice Demir, Zekiye Baydar   +3 more
doaj   +1 more source

Circulating serum HBsAg level is a biomarker for HBV-specific T and B cell responses in chronic hepatitis B patients

Scientific Reports, 2020
Chronic hepatitis B (CHB) infection functional cure is defined as sustained loss of HBsAg and several therapeutic strategies are in clinical development designed to pharmacologically reduce serum HBsAg, break immune tolerance, and increase functional ...
Jin Hyang Kim, Alip Ghosh, Natarajan Ayithan, S. Romani, A. Khanam, Jang-June Park, R. Rijnbrand, Lydia Tang, M. Sofia, S. Kottilil, Chris B. Moore, B. Poonia   +11 more
semanticscholar   +1 more source

Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis.

Gastroenterology, 2019
BACKGROUND & AIMS Seroclearance of hepatitis B surface antigen (HBsAg) is a marker for clearance of chronic hepatitis B virus (HBV) infection, but reported annual incidence rates of HBsAg seroclearance vary.
Y. Yeo, H. Ho, Hwai I. Yang, T. Tseng, T. Hosaka, H. Trinh, Min-Sun Kwak, Young Min Park, J. Fung, M. Buti, Manuel Rodríguez, S. Treeprasertsuk, C. Preda, T. Ungtrakul, P. Charatcharoenwitthaya, Xiangyong Li, Jiayi Li, Jian Q. Zhang, M. Le, Bin Wei, B. Zou, A. Le, Donghak Jeong, Nicholas Chien, Leslie Y. Kam, Chiao-Chin Lee, M. Riveiro‐Barciela, D. Istratescu, T. Sriprayoon, Y. Chong, T. Tanwandee, M. Kobayashi, F. Suzuki, M. Yuen, Hyo‐suk Lee, J. Kao, A. Lok, Chun-Ying Wu, M. Nguyen   +38 more
semanticscholar   +1 more source

Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg

Scientific Reports, 2020
Hepatitis D virus (HDV) requires hepatitis B surface antigen (HBsAg) for its assembly and release. Current HBV treatments are only marginally effective against HDV because they fail to inhibit HBsAg production/secretion.
L. Shekhtman, S. Cotler, L. Hershkovich, S. Uprichard, M. Bazinet, V. Pantea, V. Cebotarescu, Lilia Cojuhari, P. Jimbei, A. Krawczyk, U. Dittmer, A. Vaillant, H. Dahari   +12 more
semanticscholar   +1 more source

Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy

Proceedings of the National Academy of Sciences of the United States of America, 2019
Significance We detected cfDNA somatic mutations in combination with protein markers to efficiently identify early stage HCC from asymptomatic HBsAg-seropositive individuals in a community population.
C. Qu, Yuting Wang, Pei-pei Wang, Kun-Tian Chen, Min-jie Wang, H. Zeng, Jianquan Lu, Q. Song, B. Diplas, D. Tan, C. Fan, Q. Guo, Zheng Zhu, H. Yin, Liping Jiang, Xixi Chen, Hui Zhao, Huan He, Yong Wang, Guangyu Li, X. Bi, Xinming Zhao, Tao-yang Chen, Hongping Tang, Chuanguo Lv, Dongmei Wang, Wanqing Chen, Jianguo Zhou, Hong Zhao, Jianqiang Cai, Xiaoyue Wang, Sizhen Wang, Hai Yan, Y. Zeng, W. Cavenee, Y. Jiao   +35 more
semanticscholar   +1 more source

Identification by enzyme immunoassay of escape mutants S143L and G145R of hepatitis B virus (Hepadnaviridae: Orthohepadnavirus: Hepatitis B virus)

Вопросы вирусологии, 2022
Introduction. The achievement of the goal of the World Health Organization to eliminate viral hepatitis B by 2030 seems to be problematic partly due to the presence of escape mutants of its etiological agent, hepatitis B virus (HBV) (iHepadnaviridae ...
M. V. Konopleva, A. A. Feldsherova, D. A. Elgort, T. A. Tupoleva, N. A. Kokhanovskaya, V. N. Pankratova, T. A. Semenenko, A. P. Suslov   +7 more
doaj   +1 more source

Breakdown of adaptive immunotolerance induces hepatocellular carcinoma in HBsAg-tg mice

Nature Communications, 2019
Hepatitis B virus (HBV) can induce chronic inflammation, cirrhosis, and eventually hepatocellular carcinoma (HCC). Despite evidence suggesting a link between adaptive immunity and HBV-related diseases in humans, the immunopathogenic mechanisms involved ...
Lu Zong, Hui Peng, Cheng-song Sun, Fenglei Li, M. Zheng, Yongyan Chen, Haiming Wei, R. Sun, Z. Tian   +8 more
semanticscholar   +1 more source